KD疗法治疗超级难治性癫痫持续状态 (KD)
生酮饮食治疗超难治性癫痫持续状态:一项多中心、前瞻性、随机、对照试验
研究概览
详细说明
这是一项多中心、前瞻性、随机、对照、开放标签的临床研究,旨在评估生酮饮食(KD)作为超级难治性癫痫持续状态(SRSE)患者辅助治疗的有效性和安全性。
该研究计划招募符合条件的SRSE患者。参与者将按1:1的比例随机分配到以下两组之一:
- 对照组:根据当前SRSE管理指南推荐接受标准药物治疗。
- 干预组:接受标准药物治疗加生酮饮食干预。
生酮饮食干预将通过鼻饲管使用生酮配方进行。营养目标为25-30 kcal/kg,从半强度开始,并在72小时内逐步增加至全热量目标。若在开始生酮饮食后2周内未观察到临床改善,将停止干预。对于有反应者,建议继续干预。生酮饮食组的所有患者将同时接受每日营养补充剂。
主要结局指标是随机分组后2周内控制SRSE的有效性。有效性定义为临床和脑电图上的癫痫持续状态均停止,并通过连续脑电图监测确认。
关键次要结局包括:
- 安全性评估,包括所有与生酮饮食相关的不良事件和住院死亡率。
- 生酮饮食的可行性(达到酮症的时间,定义为血β-羟基丁酸水平≥1.2 mmol/L或尿酮体1+)。
- 神经功能和功能结局,通过改良Rankin量表(mRS)、格拉斯哥结局量表-扩展版(GOS-E)和生活质量量表(QOLIE-31)在出院时、3个月和6个月时评估。
- 认知功能(MMSE、MoCA)在3个月和6个月时评估。统计分析将在全分析集(FAS)和符合方案集(PPS)上进行。
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Weibi Chen
- 电话号码:0086-010-83198424
- 邮箱:chenweibi@126.com
研究联系人备份
- 姓名:Gang Liu
- 电话号码:010-83198899
- 邮箱:liugangqingyi@sina.com
学习地点
-
-
-
Beijing、中国、100730
- 尚未招聘
- Beijing Tongren Hospital, Capital Medical University
-
接触:
- Qinglin Yang
- 电话号码:0086-010-58269911
- 邮箱:lin8082@sina.com
-
Jilin、中国、130021
- 招聘中
- The First Hospital of Jilin University
-
接触:
- Jie Cao
- 电话号码:0086-0431-84808243
- 邮箱:cjie@jlu.edu.cn
-
Liaocheng、中国、252000
- 招聘中
- Liaocheng People's Hospital
-
接触:
- Dong Guo, Dr
- 电话号码:0086-0635-8276225
- 邮箱:guodonglc@126.com
-
-
Anhui
-
Hefei、Anhui、中国、230022
- 招聘中
- The First Affiliated Hospital of Anhui Medical University
-
接触:
- Yajuan Hu, Dr
- 电话号码:0086-0551-62922329
- 邮箱:78913053@qq.com
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100053
- 招聘中
- Department of Neurology, Xuanwu Hospital Capital Medical University
-
接触:
- Weibi Chen
- 电话号码:0086-010-83198899
- 邮箱:chenweibi@126.com
-
-
Fujian
-
Fuzhou、Fujian、中国、350001
- 招聘中
- Fujian Medical University Union Hospital
-
接触:
- Shenggen Chen
- 电话号码:0086-0591-83357896
- 邮箱:wanhuilin@fjmu.edu.cn
-
-
Guangxi
-
Nanning、Guangxi、中国、530021
- 招聘中
- The First Affiliated Hospital of Guangxi Medical University
-
接触:
- Zhijian Liang
- 电话号码:0086-0771-5322120
- 邮箱:lzj200415@126.com
-
-
Guizhou
-
Guiyang、Guizhou、中国、550002
- 招聘中
- Guizhou Provincial People's Hospital
-
接触:
- Xiao Hu
- 电话号码:0086-0851-85611278
- 邮箱:370704044@qq.com
-
-
Hainan
-
Haikou、Hainan、中国、570311
- 尚未招聘
- The Second Affiliated Hospital of Hainan Medical University
-
接触:
- Pengxiang Li
- 邮箱:fire_lpx1@sina.com
-
-
Hebei
-
Shijiazhuang、Hebei、中国、050031
- 招聘中
- The First Hospital of Hebei Medical University
-
接触:
- Jia Tian
- 电话号码:0086-0311-87156771
- 邮箱:541394689@qq.com
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150001
- 招聘中
- The First Affiliated Hospital of Harbin Medical University
-
接触:
- Linlin Sun
- 邮箱:sunlinlinlin1981@126.com
-
-
Neimenggu
-
Chifeng、Neimenggu、中国、024000
- 招聘中
- Chifeng Municipal Hospital
-
接触:
- Huijie Zhou
- 电话号码:0086-0476-8331476
- 邮箱:1031581493@qq.com
-
-
Shandong
-
Jinan、Shandong、中国、2500012
- 尚未招聘
- Qilu Hospital,Shandong University
-
接触:
- Qinzhou Wang
- 电话号码:0086-0531-82166666
- 邮箱:qinzhouwang@163.com
-
-
Zhejiang
-
Hanzhou、Zhejiang、中国、310009
- 招聘中
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
接触:
- Lida Su
- 电话号码:0086-0571-87783777
- 邮箱:sulida1001@zju.edu.cn
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
描述
纳入标准:
(1)诊断为超难治性癫痫持续状态(SRSE)的患者,在初始治疗(包括静脉注射苯二氮䓬类药物、抗癫痫药物(ASM,如丙戊酸、左乙拉西坦或苯巴比妥)以及连续24小时输注麻醉剂(如丙泊酚))后,癫痫持续状态(SE)持续存在或复发,或麻醉剂减量时SE复发;(2)年龄在14至80岁之间,不限性别;(3)患者的法定监护人已签署知情同意书
排除标准:
(1)患有脂质代谢障碍的患者,包括脂肪酸转运和β-氧化缺陷,如肉碱缺乏症(原发性)和肉碱相关酶缺乏症(包括肉碱棕榈酰转移酶[CPT]I和II缺乏症、肉碱转位酶缺乏症)、脂肪酸氧化障碍(包括β-氧化缺陷)、短链酰基辅酶A脱氢酶缺乏症(SCAD)、中链酰基辅酶A脱氢酶缺乏症(MCAD)、长链酰基辅酶A脱氢酶缺乏症(LCAD)、长链3-羟基酰基辅酶A脱氢酶缺乏症、中链3-羟基酰基辅酶A脱氢酶缺乏症、丙酮酸羧化酶缺乏症和卟啉症。(2)不耐受肠内喂养(如肠梗阻);(3)24小时内接受过丙泊酚输注;(4)血流动力学不稳定(收缩压<90 mmHg或舒张压<60 mmHg,需大剂量血管升压药维持);(5)肝功能衰竭(天冬氨酸氨基转移酶[AST]、丙氨酸氨基转移酶[ALT]、血氨>正常值上限5倍;总胆红素>10 g/dL [171 μmol/L]);(6)胰腺炎;(7)妊娠;(8)代谢不稳定(血糖<3.1 mmol/L,动脉血pH<7.2,血清钠<120或>160 mmol/L);(9)并发败血症;(10)并发尿崩症;(11)由缺氧缺血性脑损伤引起的癫痫持续状态。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:SRSE的标准医疗疗法和KD疗法
实验组定义为在标准药物治疗基础上添加生酮饮食
|
首先,通过鼻肠管持续启动生酮配方,以目标量的50%开始,并在72小时内增至目标量(25-30千卡/公斤/天)。
出院前,根据癫痫控制情况和耐受性继续生酮饮食方案。
如果患者接受口服营养,则启动改良的阿特金斯饮食-生酮饮食方案(碳水化合物10-20克/天)。
此外,如果出院后逐渐停止饮食,则每周减少0.5:1的比例。
Standard Medical Therapy include continuous intravenous infusion of an anesthetic agent, such as midazolam (starting regimen: 0.2 mg/kg IV bolus followed by continuous infusion of 0.1-0.6 mg/kg/h), titrated to seizure termination
|
|
有源比较器:标准护理组
主动比较组仅接受标准药物治疗。
|
Standard Medical Therapy include continuous intravenous infusion of an anesthetic agent, such as midazolam (starting regimen: 0.2 mg/kg IV bolus followed by continuous infusion of 0.1-0.6 mg/kg/h), titrated to seizure termination
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
SRSE终止时间
大体时间:2周
|
计算方法:根据脑电图(EEG)和临床癫痫发作活动,治疗效果分为三个等级: I级(无发作):电图和临床癫痫持续状态完全得到控制,随访脑电图显示电图癫痫持续状态已解决;记录达到此状态所需的天数。 II级(部分有效):癫痫样放电减少超过50%;记录达到此状态所需的天数。 III级(无效):癫痫样放电减少不足50%;记录的所需天数为14天。 |
2周
|
合作者和调查者
出版物和有用的链接
一般刊物
- van Delft R, Lambrechts D, Verschuure P, Hulsman J, Majoie M. Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine. Seizure. 2010 Jan;19(1):36-9. doi: 10.1016/j.seizure.2009.10.009. Epub 2009 Dec 3.
- Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, Whitney A, Cross JH. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008 Jun;7(6):500-6. doi: 10.1016/S1474-4422(08)70092-9. Epub 2008 May 2.
- Levy RG, Cooper PN, Giri P. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD001903. doi: 10.1002/14651858.CD001903.pub2.
- Cervenka MC, Hocker S, Koenig M, Bar B, Henry-Barron B, Kossoff EH, Hartman AL, Probasco JC, Benavides DR, Venkatesan A, Hagen EC, Dittrich D, Stern T, Radzik B, Depew M, Caserta FM, Nyquist P, Kaplan PW, Geocadin RG. Phase I/II multicenter ketogenic diet study for adult superrefractory status epilepticus. Neurology. 2017 Mar 7;88(10):938-943. doi: 10.1212/WNL.0000000000003690. Epub 2017 Feb 8.
- Thakur KT, Probasco JC, Hocker SE, Roehl K, Henry B, Kossoff EH, Kaplan PW, Geocadin RG, Hartman AL, Venkatesan A, Cervenka MC. Ketogenic diet for adults in super-refractory status epilepticus. Neurology. 2014 Feb 25;82(8):665-70. doi: 10.1212/WNL.0000000000000151. Epub 2014 Jan 22.
- Park EG, Lee J, Lee J. The ketogenic diet for super-refractory status epilepticus patients in intensive care units. Brain Dev. 2019 May;41(5):420-427. doi: 10.1016/j.braindev.2018.12.007. Epub 2019 Jan 9.
- Nabbout R, Mazzuca M, Hubert P, Peudennier S, Allaire C, Flurin V, Aberastury M, Silva W, Dulac O. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia. 2010 Oct;51(10):2033-7. doi: 10.1111/j.1528-1167.2010.02703.x. Epub 2010 Aug 31.
- Wusthoff CJ, Kranick SM, Morley JF, Christina Bergqvist AG. The ketogenic diet in treatment of two adults with prolonged nonconvulsive status epilepticus. Epilepsia. 2010 Jun;51(6):1083-5. doi: 10.1111/j.1528-1167.2009.02388.x. Epub 2009 Oct 20.
- Gilbert DL, Pyzik PL, Freeman JM. The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones. J Child Neurol. 2000 Dec;15(12):787-90. doi: 10.1177/088307380001501203.
- Arya R, Peariso K, Gainza-Lein M, Harvey J, Bergin A, Brenton JN, Burrows BT, Glauser T, Goodkin HP, Lai YC, Mikati MA, Fernandez IS, Tchapyjnikov D, Wilfong AA, Williams K, Loddenkemper T; pediatric Status Epilepticus Research Group (pSERG). Efficacy and safety of ketogenic diet for treatment of pediatric convulsive refractory status epilepticus. Epilepsy Res. 2018 Aug;144:1-6. doi: 10.1016/j.eplepsyres.2018.04.012. Epub 2018 Apr 27.
- Lindefeldt M, Eng A, Darban H, Bjerkner A, Zetterstrom CK, Allander T, Andersson B, Borenstein E, Dahlin M, Prast-Nielsen S. The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy. NPJ Biofilms Microbiomes. 2019 Jan 23;5(1):5. doi: 10.1038/s41522-018-0073-2. eCollection 2019.
- Zhang Y, Zhou S, Zhou Y, Yu L, Zhang L, Wang Y. Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet. Epilepsy Res. 2018 Sep;145:163-168. doi: 10.1016/j.eplepsyres.2018.06.015. Epub 2018 Jun 28.
- Tagliabue A, Ferraris C, Uggeri F, Trentani C, Bertoli S, de Giorgis V, Veggiotti P, Elli M. Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 Deficiency Syndrome: A 3-month prospective observational study. Clin Nutr ESPEN. 2017 Feb;17:33-37. doi: 10.1016/j.clnesp.2016.11.003. Epub 2016 Dec 18.
- Singh RK, Joshi SM, Potter DM, Leber SM, Carlson MD, Shellhaas RA. Cognitive outcomes in febrile infection-related epilepsy syndrome treated with the ketogenic diet. Pediatrics. 2014 Nov;134(5):e1431-5. doi: 10.1542/peds.2013-3106.
- Li Y, Yang X, Zhang J, Jiang T, Zhang Z, Wang Z, Gong M, Zhao L, Zhang C. Ketogenic Diets Induced Glucose Intolerance and Lipid Accumulation in Mice with Alterations in Gut Microbiota and Metabolites. mBio. 2021 Mar 30;12(2):e03601-20. doi: 10.1128/mBio.03601-20.
- Mahmoud SH, Ho-Huang E, Buhler J. Systematic review of ketogenic diet use in adult patients with status epilepticus. Epilepsia Open. 2019 Nov 24;5(1):10-21. doi: 10.1002/epi4.12370. eCollection 2020 Mar.
- Yudkoff M, Daikhin Y, Horyn O, Nissim I, Nissim I. Ketosis and brain handling of glutamate, glutamine, and GABA. Epilepsia. 2008 Nov;49 Suppl 8(Suppl 8):73-5. doi: 10.1111/j.1528-1167.2008.01841.x.
- Lowe H, Keller AE, Tanzini E, Aimola S, Liu YMC, Zak M, Chan V, Kobayashi J, Donner EJ. Ketonuria and Seizure Control in the Medium Chain Triglyceride and Classic Ketogenic Diets. Can J Neurol Sci. 2022 May;49(3):433-436. doi: 10.1017/cjn.2021.122. Epub 2021 Jun 2.
- Kaul N, Nation J, Laing J, Nicolo JP, Deane AM, Udy AA, Kwan P, O'Brien TJ. Modified low ratio ketogenic therapy in the treatment of adults with super-refractory status epilepticus. JPEN J Parenter Enteral Nutr. 2022 Nov;46(8):1819-1827. doi: 10.1002/jpen.2373. Epub 2022 Apr 7.
- van der Louw E, Aldaz V, Harvey J, Roan M, van den Hurk D, Cross JH, Auvin S; Review Group. Optimal clinical management of children receiving ketogenic parenteral nutrition: a clinical practice guide. Dev Med Child Neurol. 2020 Jan;62(1):48-56. doi: 10.1111/dmcn.14306. Epub 2019 Jul 16.
- Kaul N, Laing J, Nicolo JP, Nation J, Kwan P, O'Brien TJ. Practical Considerations for Ketogenic Diet in Adults With Super-Refractory Status Epilepticus. Neurol Clin Pract. 2021 Oct;11(5):438-444. doi: 10.1212/CPJ.0000000000001009.
- Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020 Jun 24;6(6):CD001903. doi: 10.1002/14651858.CD001903.pub5.
- Buchhalter JR, D'Alfonso S, Connolly M, Fung E, Michoulas A, Sinasac D, Singer R, Smith J, Singh N, Rho JM. The relationship between d-beta-hydroxybutyrate blood concentrations and seizure control in children treated with the ketogenic diet for medically intractable epilepsy. Epilepsia Open. 2017 May 19;2(3):317-321. doi: 10.1002/epi4.12058. eCollection 2017 Sep.
- Breu M, Hafele C, Glatter S, Trimmel-Schwahofer P, Golej J, Male C, Feucht M, Dressler A. Ketogenic Diet in the Treatment of Super-Refractory Status Epilepticus at a Pediatric Intensive Care Unit: A Single-Center Experience. Front Neurol. 2021 Jun 3;12:669296. doi: 10.3389/fneur.2021.669296. eCollection 2021.
- Francis BA, Fillenworth J, Gorelick P, Karanec K, Tanner A. The Feasibility, Safety and Effectiveness of a Ketogenic Diet for Refractory Status Epilepticus in Adults in the Intensive Care Unit. Neurocrit Care. 2019 Jun;30(3):652-657. doi: 10.1007/s12028-018-0653-2.
- Caraballo RH, Flesler S, Armeno M, Fortini S, Agustinho A, Mestre G, Cresta A, Buompadre MC, Escobal N. Ketogenic diet in pediatric patients with refractory focal status epilepticus. Epilepsy Res. 2014 Dec;108(10):1912-6. doi: 10.1016/j.eplepsyres.2014.09.033. Epub 2014 Oct 13.
- Appavu B, Vanatta L, Condie J, Kerrigan JF, Jarrar R. Ketogenic diet treatment for pediatric super-refractory status epilepticus. Seizure. 2016 Oct;41:62-5. doi: 10.1016/j.seizure.2016.07.006. Epub 2016 Jul 21.
- Goswami JN, Sharma S. Current Perspectives On The Role Of The Ketogenic Diet In Epilepsy Management. Neuropsychiatr Dis Treat. 2019 Nov 25;15:3273-3285. doi: 10.2147/NDT.S201862. eCollection 2019.
- Dahlin M, Hjelte L, Nilsson S, Amark P. Plasma phospholipid fatty acids are influenced by a ketogenic diet enriched with n-3 fatty acids in children with epilepsy. Epilepsy Res. 2007 Feb;73(2):199-207. doi: 10.1016/j.eplepsyres.2006.10.005. Epub 2006 Dec 5.
- Masino SA, Rho JM. Mechanisms of Ketogenic Diet Action. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012. Available from http://www.ncbi.nlm.nih.gov/books/NBK98219/
- Bromfield E, Dworetzky B, Hurwitz S, Eluri Z, Lane L, Replansky S, Mostofsky D. A randomized trial of polyunsaturated fatty acids for refractory epilepsy. Epilepsy Behav. 2008 Jan;12(1):187-90. doi: 10.1016/j.yebeh.2007.09.011.
- Abdallah DM. Anticonvulsant potential of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in pentylenetetrazole-induced acute seizures and kindling in mice. Brain Res. 2010 Sep 10;1351:246-253. doi: 10.1016/j.brainres.2010.06.034. Epub 2010 Jun 21.
- Trinka E, Kalviainen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure. 2017 Jan;44:65-73. doi: 10.1016/j.seizure.2016.11.001. Epub 2016 Nov 14.
- Kantanen AM, Reinikainen M, Parviainen I, Ruokonen E, Ala-Peijari M, Backlund T, Koskenkari J, Laitio R, Kalviainen R. Incidence and mortality of super-refractory status epilepticus in adults. Epilepsy Behav. 2015 Aug;49:131-4. doi: 10.1016/j.yebeh.2015.04.065. Epub 2015 Jul 2.
- Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011 Oct;134(Pt 10):2802-18. doi: 10.1093/brain/awr215. Epub 2011 Sep 13.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- KS2025230-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.